Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
- 1 October 2014
- journal article
- vaccine reports
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 33 (10), 1065-1076
- https://doi.org/10.1097/inf.0000000000000459
Abstract
Background: Pneumococcal conjugate vaccine (PCV) antibody persistence and immunologic memory responses may be indicative of protection in previously vaccinated children. In children vaccinated in a previous study with an infant/toddler regimen of 4 doses of PCV7, 4 doses of PCV13, or 3 doses of PCV7 (infant series) and a dose of PCV13 (toddler dose), this follow-on study evaluated antibody persistence ≥24 months after the toddler dose, and immunogenicity and safety of a follow-on dose of PCV13. Methods: Children ≥3 years of age who had completed the initial study received 1 dose of PCV13 in this phase 3, open-label follow-on study in France. Serotype-specific anticapsular immunoglobulin G (IgG) and functional opsonophagocytic activity (OPA) were compared across the previous study vaccination groups, before, 4–7 days (IgG only), and 1 month after follow-on vaccination. Safety was assessed. Results: Before follow-on vaccination, IgG and OPA levels for the PCV7 serotypes were comparable across vaccination groups, but were generally higher for the 6 additional serotypes in children who received PCV13 in the previous study. At both time points after the follow-on vaccination, IgG and OPA values for all 13 serotypes increased, those for the PCV7 serotypes were similar across vaccination groups, but concentrations for the additional serotypes were higher in children who had received PCV13 in the previous study. PCV13 was well-tolerated. Conclusions: Antibody persistence and rapid responses after a follow-on dose of PCV13 suggest that even a single toddler dose of PCV13 is likely to provide protection against the 6 additional PCV13 serotypes.Keywords
This publication has 25 references indexed in Scilit:
- Impact of Introduction of Conjugate Vaccines in the Vaccination Schedule on the Incidence of Pediatric Invasive Pneumococcal Disease Requiring Hospitalization in Madrid 2007 to 2011The Pediatric Infectious Disease Journal, 2013
- Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2013
- Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccineVaccine, 2011
- Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccineEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and ToddlersPublished by American Academy of Pediatrics (AAP) ,2010
- Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyVaccine, 2010
- Postlicensure Surveillance for Pneumococcal Invasive Disease After Use of Heptavalent Pneumococcal Conjugate Vaccine in Northern California Kaiser PermanenteThe Pediatric Infectious Disease Journal, 2004
- Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trialThe Lancet, 2003
- Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccineThe Pediatric Infectious Disease Journal, 2001
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000